Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Suspended 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 18INDUSTRY 10NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2CNS 1

Conditions

Multiple Myeloma 2Neuroblastoma 1Ganglioneuroblastoma 1

Interventions

Specimen Handling 354Magnetic Resonance Spectroscopy 252Biopsy 222Nivolumab 69Cyclophosphamide 65Carboplatin 56Radiation 53Paclitaxel 53X-Rays 52pembrolizumab 51Taxes 51Immunoglobulin G 51Disulfides 51Cisplatin 49Platinum 451,2-diaminocyclohexaneplatinum II citrate 45Doxorubicin 44Radiotherapy 42Ipilimumab 38atezolizumab 37fludarabine 35Gemcitabine 35CTLA-4 Antigen 35olaparib 32Vincristine 31Prednisone 31Bevacizumab 30venetoclax 27Cytarabine 27Phantoms, Imaging 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × iberdomide × 1 year × Clear all
NCT06179888 2026-06-11

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Suspended
78 enrolled
Plasma cell

Multiple Myeloma

NCT06465316 2026-05-27

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Recruiting
26 enrolled
Plasma cell

Multiple Myeloma

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡